SW620 (KRAS G12V), DLD-1 (KRAS G13D) and KRAS wild-type CRC (HCT8 and HT29) cells were transfected with CDK4 siRNA, FYN siRNA, both CDK4 siRNA and FYN siRNA, or scramble control siRNA for 48 h; then, immunoblotting was performed to verify if these siRNAs specifically reduced the expression of CDK4 and FYN (Fig. s1a). Here, KRAS is linked to colorectal carcinoma.